NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) CFO Patrick Williams bought 11,891 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The shares were bought at an average price of $8.34 per share, for a total transaction of $99,170.94. Following the transaction, the chief financial officer directly owned 79,399 shares in the company, valued at $662,187.66. This trade represents a 17.61% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
NeuroPace Stock Down 1.0%
Shares of NASDAQ NPCE opened at $8.14 on Friday. The company has a quick ratio of 4.09, a current ratio of 5.26 and a debt-to-equity ratio of 5.15. The firm has a market cap of $280.42 million, a PE ratio of -14.54 and a beta of 1.98. The company’s fifty day simple moving average is $12.70 and its 200 day simple moving average is $14.60. NeuroPace, Inc. has a 12-month low of $5.46 and a 12-month high of $19.60.
Institutional Trading of NeuroPace
Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of NeuroPace in the second quarter valued at $39,369,000. GSA Capital Partners LLP acquired a new position in shares of NeuroPace during the second quarter valued at about $1,836,000. First Light Asset Management LLC increased its position in shares of NeuroPace by 16.3% during the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after acquiring an additional 401,201 shares in the last quarter. Deutsche Bank AG bought a new stake in shares of NeuroPace during the second quarter worth about $14,919,000. Finally, Man Group plc bought a new stake in shares of NeuroPace during the second quarter worth about $1,336,000. Institutional investors and hedge funds own 78.83% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on NPCE shares. Wall Street Zen lowered shares of NeuroPace from a “hold” rating to a “sell” rating in a report on Saturday, November 14th. Raymond James Financial set a $21.00 target price on NeuroPace in a research note on Tuesday, September 15th. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. KeyCorp dropped their price target on NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, November 13th. Finally, Wells Fargo & Company lowered NeuroPace from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $19.00 to $9.00 in a report on Friday, November 13th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.11.
Read Our Latest Stock Analysis on NeuroPace
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Recommended Stories
- Five stocks we like better than NeuroPace
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
